Biocon Q3 net profit falls 25 per cent; revenue up 36 per cent at Rs 3,020 crore

The company's net R&D investments for the quarter grew by 144% to Rs 337 crore, representing 16% of revenues ex-Syngene.

published on : 15th February 2023

Biocon Biologics recognised for great managers

Biocon Biologics is among the top 50 companies of the 175 that participated to feature on this list. 

published on : 23rd December 2022

Shreehas Tambe named MD and CEO of Biocon Biologics

Tambe takes over from Arun Chandavarkar, who will continue to serve as a non-executive, non-independent Director on the Board of Biocon Biologics.

published on : 5th December 2022

Biocon arm closes multi-billion buyout

The balance has been funded through an equity infusion of $650 million by Biocon Limited and $150 million by Serum Institute Life Sciences (SILS), the company said in a statement.

published on : 30th November 2022

'Does govt care?': Biocon chief on poor roads in Bengaluru

Her tweet comes after a campaign by residents when school children were stuck in traffic for two-and-a-half hours, and were forced to return home without attending school on Wednesday.

published on : 11th November 2022

John Shaw, husband of Biocon chairperson Kiran Mazumdar-Shaw, passes away

He had 27 years of experience with Coats Viyella plc. in various capacities including finance and general administration around the world before joining the board of Biocon Ltd in 1999.

published on : 24th October 2022

Bengaluru rain havoc: Devastating, says Kiran Mazumdar-Shaw 

Mazumdar-Shaw said building codes need to be redrawn and called for a corrective and preventive action plan after a "post-hoc analysis" of root causes.

published on : 6th September 2022

CBI files charge sheet in Rs 9 lakh Biocon bribery case

The agency has alleged that the bribe payment was being paid to Joint Drug Controller S Eswara Reddy after clearance from associate vice president of Biocon Biologics L Praveen Kumar.

published on : 25th August 2022

Biocon Q1 profit rises 71 per cent, revenue up 23 per cent

 Its core EBITDA grew 25 per cent and margin improved to 31 per cent compared to 30 per cent in Q1FY22.

published on : 27th July 2022

CBI arrests Biocon executive, four others in bribery case

Praveen Kumar was arrested from Bengaluru and taken to Delhi on Tuesday on transit remand.

published on : 23rd June 2022

What’s this road! Angry Kiran Mazumdar-Shaw slams Karnataka govt

Biocon, one of the biggest Bengaluru-based companies, is unhappy with the quality of roads in the state capital.

published on : 7th June 2022

Biocon founder Kiran Mazumdar-Shaw’s mother passes away at 91

Biocon Chairperson Kiran Mazumdar-Shaw’s mother Yamini passed away at 91, here on Friday.

published on : 4th June 2022

Biocon Q4 net profit down 4 per cent

Its consolidated revenue from operations in the fourth quarter stood at Rs 2,409 crore, a 30.7% increase compared to Rs 1,842 crore in the year-ago period.

published on : 29th April 2022

Biocon Biologics' arm gets USD 90 million contract from Malaysia for supply of insulins

More recently, Biocon's biosimilar insulin Glargine made in Malaysia, has received an USFDA approval as the 'first interchangeable biosimilar'.

published on : 26th April 2022

Kiran Mazumdar-Shaw expresses concern over communal rift

Taking to Twitter, Shaw said Karnataka has always forged inclusive economic development and the government must not allow such communal exclusion.

published on : 1st April 2022

Biocon arm to buy Biosimilars business of Viatris

BBL acquires Viatris’ global biosimilars business with an estimated revenue of $875 million and EBITDA of $200 million for CY 2022 and estimated to exceed $1 billion in revenue next year.

published on : 1st March 2022

COVID-19 has created an 'ecosystem' of innovation in India: Biocon chief Kiran Mazumdar-Shaw

Mazumdar-Shaw is one of the key speakers at the 15th edition of the annual virtual summit on June 22 hosted by the USA India Chambers of Commerce.

published on : 15th June 2021